Genetic and epigenetic sequencing are pivotal in biomarker discovery, offering unparalleled accuracy, throughput, and adaptability for both research and clinical applications. These tools are at the forefront of understanding complex diseases, driving the future of healthcare through precision medicine.
At Wasatch BioLabs, we specialize in discovering and validating biomarkers that reflect true biological signals. Our services include comprehensive whole-genome approaches and targeted solutions, providing researchers and clinicians with accurate, high-throughput tools positioned to revolutionize diagnostics and patient care.
Unlike standard NGS solutions, WBL’s proprietary NESSI-Seq platform sequences native DNA, eliminating amplification biases, batch effects, and DNA damage from chemical treatments like sodium bisulfite. Leveraging a proprietary library preparation protocol that enhances sensitivity, specificity, and data quality, and Nanopore sequencing, NESSI-Seq technology excels with challenging biological samples like highly fragmented cfDNA and DNA extracted from formalin-fixed tissues. It preserves methylation data across all 27 million CpG sites, and utilizes long-read sequencing for detailed structural variant analysis, offering unparalleled insights for complex genomic and epigenomic studies.
